Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.

@article{Passos2002LongtermFO,
  title={Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.},
  author={V. Passos and J. J. Souza and N. Musolino and M. Bronstein},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2002},
  volume={87 8},
  pages={
          3578-82
        }
}
Bromocriptine (BRC) and other dopamine agonist drugs are the first-choice treatment for prolactinomas. However, the major disadvantage is the need for prolonged therapy. We retrospectively studied 131 patients [62 microprolactinoma (MIC), 69 macroprolactinoma (MAC)], who achieved serum prolactin (PRL) normalization during BRC use. Twenty-seven percent of them (31% MIC and 69% MAC) underwent previous surgery. Twenty-seven patients (20.6%: 25.8% MIC and 15.9% MAC) persisted with… Expand
Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
Long-term control of macroprolactinomas
  • M. Bronstein
  • Medicine
  • Expert review of endocrinology & metabolism
  • 2008
Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.
Necrotic changes in prolactinomas after long term administration of bromocriptine.
...
1
2
3
...